Posts tagged Janney Capital


Nike Wows Investors With A Stellar Q1

Nike, Inc. (NYSE: NKE) is a Beaverton, Oregon based American multinational corporation that designs, develops, manufactures …

Janney Capital Remains Neutral On PDL Biopharma Following The Resign Of Ernst & Young

In a research note released today, Janney Capital analyst Kimberly Lee maintained a Neutral rating on PDL …

Janney Reiterates Buy On CTI BioPharma Following Collaboration Agreement With Servier

In a research note published today, Janney Capital analyst Kimberly Lee maintained a Buy rating on Cell …

Janney Capital Reiterates Buy On Agile Therapeutics Following Initiation Of Phase III Twirla Study

In a research note released today, Janney Capital analyst Kimberly Lee reiterated a Buy rating …

Janney Reiterates Buy On NPS Pharmaceuticals As FDA Panel Backs Natpara Approval

In a report released today, Janney Capital analyst Kimberly Lee reiterated a Buy rating on NPS Pharmaceuticals (NASDAQ:NPSP) with …

Janney Capital Reiterates Buy On NPS Pharma Ahead Of FDA Meeting For Natpara

In a research note published yesterday, Janney Capital analyst Kimberly Lee reiterated a Buy rating …

Janney Capital Keeps Buy On Medivation Following Label Expansion On Xtandi

In a research report pubished yesterday, Janney Capital analyst Kimberly Lee maintained a Buy rating …

We Remain Constructive On NPSP Shares Ahead Of The Upcoming FDA AdCom, Says Janney

In a research report released today, Janney Capital analyst Kimberly Lee reiterated a Buy rating on NPS Pharmaceuticals (NPSP) …

Janney Capital Sees 42% Upside In Amicus Therapeutics Following Positive Phase 3 Data

Amicus Therapeutics (FOLD) today announced robust 18-month data from the migalastat monotherapy Study 012 in …

Raptor Quarterly Update: Janney Capital Suggests Buying Shares

In a research note released August 8, Janney Capital analyst Kimberly Lee maintained a Buy …

Show More